Arformoterol tartrate

Arformoterol tartrate

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Arformoterol
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	nebuliser
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	52–65%
Elimination half-life	26 hours
Identifiers
IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2- (2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
CAS Number	67346-49-0
DrugBank	DB01274
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H24N2O4
Molar mass	344.405 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Arformoterol, also known as arformoterol tartrate (USAN) is a long acting beta-adrenoceptor agonist drug indicated for the treatment of COPD. It is sold by Sepracor, under the tradename Brovana, as a solution to be administered twice daily (morning and evening) by nebulization.

It is the active (R,R)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.

External links

• Brovana website

Template:WikiDoc Sources